Vectura Group plc specialises in developing inhaled therapies, principally for the treatment of respiratory diseases.
Vectura has a broad pipeline of products in development that use its proprietary device and formulation technologies and, also has a portfolio of revenue-generating, marketed products.
Product pipeline: Vectura has a broad development pipeline that combines mid and late stage programmes with earlier stage opportunities:
Respiratory
NVA237/COPD
QVA149/COPD
VR315/asthma/COPD
VR632/asthma/COPD
VR506/asthma
VR496/cystic fibrosis/COPD
Duohaler® Projects/asthma/COPD
Neurology
VR040/Parkinson's disease
VR147/migraine
Other indications
VR004/erectile dysfunction
VR776/premature ejaculation
Marketed products: Vectura receives royalty income from a portfolio of eight revenue-generating, marketed products, both respiratory and non-respiratory products, which helps to funds Vectura’s product development, listed as follows:
ADVATE®
Extraneal®
Adept®
Asmasal®
Asmabec®
Meptin® Clickhaler®
Proprietary technologies: Vectura has the complete range of device and formulation technologies (listed below) to take an API and deliver a finished inhaled pharmaceutical product. Vectura has proven its ability to industrialise its products for marketing purposes.
GyroHaler®
OmniHaler®
Aspirair®
Clickhaler®
Duohaler®
PowderHale®
Other formulation techniques
Vectura’s product development strategy is to combine its proprietary device and formulation technologies with existing off-patent or clinically validated drugs, some of which are repurposed to treat new indications, with inhalation as an improved, more effective route of delivery, or to treat the same indication, with inhalation as an improved, more effective route of delivery.
Partnerships: Vectura develops pulmonary products in-house and in collaboration with its pharmaceutical partners and out-licenses certain products that require significant resources for later stage development and commercialisation. The Company also selectively out-licenses its device and formulation technologies to other companies. It's partners include Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK),
Intellectual property: Vectura protects its products and technologies, which include patents, trademarks, design rights and confidential know-how. The patent portfolio comprises about 110 families with patents in the key territories of the United States, Japan and the main European member states. Vectura vigorously maintains and protects its intellectual property estate.
Vectura’s Executive Management team:
Dr Chris Blackwell, Chief Executive
Anne Hyland, Chief Financial Officer and Company Secretary
Dr Trevor Phillips, Chief Operations Officer & President US Operations
Dr Tim Wright, Commercial Director
Dr Mark Main, Development Director
Dr Martin Shott, Pharmaceutical Operations Director
Stephen Eason, Director of Device Development
The Board of Directors:
John “Jack” Cashman, Non-Executive Chairman
Dr Susan Foden, Non-Executive Director
Dr John Brown, Non-Executive Director
Neil Warner, Non-Executive Director
Dr Chris Blackwell, Chief Executive
Anne Hyland, Chief Financial Officer and Company Secretary
Locations: Vectura is based in the UK with headquarters and development operations in Chippenham, Wiltshire with device development in Cambridge and a small office in Boston, US.
LSE listed: Vectura’s shares are traded on the London Stock Exchange under the symbol VEC.